+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Verge Genomics - Tech Innovator Profile

  • PDF Icon

    Company Profile

  • 10 Pages
  • November 2022
  • GlobalData
  • ID: 5008632
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Founded in 2015, Verge Genomics is an AI-driven biopharmaceutical drug discovery company that applies patient genomes, epigenomics, and gene expression for identifying novel effective drugs; stratify patient subpopulations, and therapeutic gene targets for accelerating clinical success. Verge Genomics is focusing on three neurodegenerative diseases: frontotemporal dementia (FTD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).

Scope

The report provides information and insights into Verge Genomics, including:

  • Overview of the company and its product offering
  • Detailed insight into its business model, company type and headquarter
  • Information on funding and partnership
  • Biography of top management

Reasons to Buy

  • Gain insights into Verge Genomics' business operations
  • Gain insights into partnership and funding
  • Gain understanding about its technology focus

Table of Contents

  • Overview
  • Technology Focus
  • Product Overview
  • Partnerships & Funding
  • Key Employees
  • Appendix

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Eli Lilly and Company
  • Sheffield Institute for Translational Neuroscience (SITraN)
  • Genomics England
  • Datavant